ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Under pressure from unions and the French government, Sanofi, France’s largest drugmaker, has decided not to close a research site in Toulouse, France, where it employs about 640 scientists. The firm had been contemplating shuttering the site as part of a cost-reduction plan for its home country. Sanofi expects to change the site’s role, however. Options being considered include developing a technology services business, spinning off drug discovery activities, and housing local start-ups. The firm will continue with its plan to consolidate R&D in Paris, Lyon, and Strasbourg and transform its Montpellier R&D site into a group development center.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X